Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics

Andrew J. Solomon, Eran P. Klein, John R. Corboy, James L. Bernat

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: Pharmaceutical industry financial support of physicians, physician practices, and academic departments involved in multicenter industry-sponsored clinical trials of novel therapeutic agents is a relatively new and infrequently acknowledged source of potential physician conflict of interest. Detailed disclosure of these relationships to study participants is not uniformly a part of informed consent and documentation practices. Objective: To understand attitudes of patients with multiple sclerosis concerning disclosure of potential physician-industry conflicts of interest created by clinical trials and how such disclosures may influence study participation Methods: An anonymous online instrument was developed. Results: 597 people with multiple sclerosis participated in the study. The study found that detailed disclosure of conflicts of interest is important to potential participants in industry-sponsored clinical trials for multiple sclerosis therapies and that the presence of these conflicts of interest may influence patients' decisions to participate in these studies. Conclusions: Findings from this study support a call for uniform guidelines regarding disclosure of physician-industry relationships to prospective research participants for industry-sponsored clinical trials.

Original languageEnglish (US)
Pages (from-to)1593-1599
Number of pages7
JournalMultiple Sclerosis
Volume21
Issue number12
DOIs
StatePublished - Oct 1 2015

Keywords

  • Multiple sclerosis
  • clinical trials
  • conflict of interest
  • industry-sponsored clinical trials
  • professional conduct and ethics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics'. Together they form a unique fingerprint.

  • Cite this